A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female ≥18 years of age
• Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
• Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
• Adequate hematological, renal and hepatic function
• Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners
Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Florida
H Lee Moffitt Cancer Center & Research Institute
RECRUITING
Tampa
Georgia
Winship Cancer Institute
RECRUITING
Atlanta
Maryland
American Oncology Partners, PA
RECRUITING
Bethesda
Missouri
Washington University School of Medicine
RECRUITING
St Louis
North Carolina
Levine Cancer Institute
RECRUITING
Charlotte
Wake Forest University Health Sciences
RECRUITING
Winston-salem
Nebraska
University of Nebraska Medical Center
RECRUITING
Omaha
New Jersey
Rutgers Cancer Institute of New Jersey
RECRUITING
New Brunswick
Ohio
Cleveland Clinic
RECRUITING
Cleveland
Pennsylvania
University of Pennsylvania, Abramson Cancer Center
RECRUITING
Philadelphia
Washington
Fred Hutchinson Cancer Center
RECRUITING
Seattle
Other Locations
United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
RECRUITING
Bebington
University Hospital of Wales
RECRUITING
Cardiff
Western General Hospital
RECRUITING
Edinburgh
Barts Health NHS Trust
RECRUITING
London
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITING
London
King's College Hospital NHS Foundation Trust
RECRUITING
London
Royal Marsden NHS Foundation Trust
RECRUITING
Sutton
The Christie NHS Foundation Trust
RECRUITING
Withington
Contact Information
Primary
CCS1477-04 Clinical Operations
DOMMINO-1@cellcentric.com
+44 1799 531130
Time Frame
Start Date:2026-01-22
Estimated Completion Date:2029-12-01
Participants
Target number of participants:100
Treatments
Experimental: Inobrodib in combination with pomalidomide and dexamethasone